Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
Advances in blood cancer treatment have saved 25.8 million life-years, with significant gains for Hodgkin lymphoma and non-Hodgkin lymphoma patients. However, Black patients and those with acute myeloid leukemia (AML) continue to experience worse outcomes, highlighting the need for continued research investment.
Researchers at UC San Diego will develop optimized red blood cells to temporarily boost human performance and health through enhanced oxygen delivery. The project has the potential to improve athletic performance and treat conditions involving oxygen delivery to tissues.
Immunotherapy for gynecological tumors offers durable responses and survival benefits, but complex immune evasion mechanisms and tumor microenvironment pose challenges. Current treatment options, such as ICIs and adoptive cell therapy, show promise, but precision immunotherapy is needed to improve patient outcomes.
A large international study found that routine referrals to cardiologists or internists improved cholesterol levels in prostate cancer patients, but did not lead to fewer heart attacks, strokes, or cardiovascular deaths. Researchers noted that fewer participants experienced these complications than expected, making it harder to determi...
Researchers have created a high-resolution functional map of human immune cells, revealing intricate circuits that govern health and disease. The dataset provides a powerful framework for designing cancer immunotherapies and treating autoimmune conditions, and serves as a foundation for AI models of biology.
Researchers discovered how tumors interact with the body to grow and spread, revealing a new target for cancer therapy. Metadherin, a protein encoded by the MTDH gene, mediates this metabolic-immune crosstalk, supporting tumor growth and metastasis.
Researchers developed fluorescent molecules that allow imaging of DNA inside living cells at unprecedented resolution, and in preserved cells, close to the width of the double helix. The team tested the probes on cancer patients and found DNA to be noticeably looser and more spread out in tumours.
Cyclin D1, a protein linked to cancer, paradoxically promotes chronic inflammation in non-proliferating senescent cells, which can lead to age-related disease. Research suggests that targeting cyclin D1 may be a promising strategy to reduce inflammation and promote healthier aging.
A new study reveals that pre-cancerous blood cells can actively reshape the bone marrow environment, creating conditions that favor their growth and increasing the risk of blood cancer. By targeting the aging bone marrow environment, scientists may be able to slow down or prevent blood cancers before they arise.
A UCLA study found that patients with cancer who used biosimilars had lower average monthly costs for insurers and patients, with savings of $3,820 for insurers and $39.50 for patients. The study also found that biosimilar entry led to lower prices and declining market share for the original branded biologic drugs.
Researchers at the University of Massachusetts Amherst have been awarded $2.5 million to adapt their nanoparticle vaccine research to treat existing cancer. The prime-pull approach will deliver immune-activating medicines to both lymph nodes and tumors to create a robust immune response.
Researchers at CU Anschutz and Indiana University School of Medicine identified a biological process that explains how colorectal cancer can cause severe muscle and bone loss. Blocking the production of a protein called IGFBP1 helped preserve muscle and bone, improving muscle strength in laboratory and preclinical models.
Native Hawaiian women have the highest breast cancer incidence in the US, with a 27% higher rate than White women. The American Cancer Society report highlights the need for tailored interventions to address cancer disparities among Asian American and Native Hawaiian and Pacific Islander populations.
A multicenter study found that early rasburicase treatment can significantly reduce the risk of dialysis and death in adults with tumor lysis syndrome. The study analyzed data from 1,276 patients and showed that early rasburicase treatment was associated with lower 90-day mortality and faster return to cancer therapy.
UM171 molecule helps retain stem cell properties, stimulating multiplication, and exploits protein KBTBD4 to break down important protein structure CoREST. This mechanism is also affected by mutations in KBTBD4 gene, linked to aggressive brain tumours in children.
A prospective multicenter study found the EAP regimen delivered outstanding mobilization effects, achieving 90.8% optimal mobilization in patients. The regimen showed good clinical tolerability, with most hematological toxicities well managed, and presented a practical alternative to conventional mobilization strategies.
Researchers emphasize the need for personalized drug delivery systems that consider tumor biology, location, and patient factors to effectively treat oral cancer. Mucoadhesive films, oral sprays, and injectable hydrogels are promising technologies, but their translation to clinical use depends on practical considerations.
This special issue of Cancer Biology & Medicine presents a comprehensive snapshot of global cancer incidence and mortality, highlighting emerging trends and risk factors. The collection offers actionable insights for prevention and early detection, leveraging large-scale population data and innovative analytical frameworks.
The RENI-1 study found durable and clinically meaningful outcomes for niraparib maintenance therapy in ovarian cancer patients, with median PFS reaching 36.5 months. Long-term niraparib use was feasible, particularly in patients with BRCA1/2 mutations, and did not adversely affect quality of life.
Researchers at Keck School of Medicine of USC will investigate PFAS as a risk factor for liver and endometrial cancers. The studies aim to understand the biological mechanisms linking PFAS exposure to cancer risk and identify ways to mitigate that risk.
Researchers created a detailed map of B cell development and behavior in melanoma tumours, revealing new insights into immunotherapy response. The study identified an 'inflamed' B cell state that persists throughout disease progression and after treatment.
The study found that Ct-HBx upregulates PAI-1 by opening chromatin and trans-activating its expression, increasing hepatocellular carcinoma risk and prognosis. PAI-1 levels and genetic polymorphisms serve as biomarkers for predicting HCC risk and postoperative prognosis.
A new Cochrane review finds that nicotine e-cigarettes are more effective in helping people quit smoking than conventional methods like nicotine gums and patches. The review of 80 randomized controlled trials involving 29,861 participants showed that e-cigarettes led to higher quit rates, resulting in about 4 more quitters per 100 people.
Researchers have developed an mRNA immunotherapy that eliminates pancreatic tumors in mice, achieving complete tumor responses and long-term disease-free periods. The treatment uses a cocktail of immune cytokine and tumor-associated antigen mRNAs, showing promise as a potential transformative treatment for pancreatic cancer.
UCSF scientists have invented a way to treat cancer with teacher cells and tumor pieces, combining immune cells grown in the lab with patient tumor samples. The method uses dendritic cells to train T cells to recognize and destroy cancer cells, offering a promising approach to immunotherapy.
Researchers found that radiation to the thymus during NSCLC treatment increased cancer spread and mortality risk in patients with relatively healthy thymus. Thymic health scores were associated with T-cell diversity, longevity, and cancer outcomes.
Amino acid sensors play a crucial role in regulating tumor biology by linking nutrient availability to tumor adaptation and immune evasion. Targeting these sensing pathways may expose metabolic vulnerabilities and provide new opportunities for combination cancer therapy.
Researchers at Purdue University have developed L-32, a quinolone-based inhibitor that targets PTPN22, a negative regulator of the immune system. This compound promotes robust antitumor immunity and has improved potency, selectivity, and cellular efficacy compared to previous derivatives.
A new blood-based approach developed by Kumamoto University researchers detects breast cancer recurrence by analyzing nucleosome structure in circulating DNA. The study identified genomic regions associated with treatment resistance and recurrence, promising a low-invasive monitoring method for patients.
A new study by Mass General Brigham researchers identifies dual specificity phosphatase 5 (Dusp5) and zinc finger protein 219 (Zfp219) as key regulators of T cell dysfunction in cancer. The findings suggest that blocking Zfp219 activity could be a promising approach to improving T cell function in older adults, potentially leading to b...
Dr. Georg Aue, a nationally recognized blood cancer expert, has been named the inaugural director of the Stem Cell Transplant and Cellular Therapy Program at UT Health San Antonio. The program aims to increase access to new therapeutic approaches for patients across South Texas, with a focus on clinical excellence, research innovation,...
Researchers developed a spatially programmable microfluidic chip for temperature-controlled separation of particles of multiple sizes in a single device. The device successfully separated multiple particle populations and isolated viable cancer cells, white blood cells, and red blood cells from diluted whole blood.
A new study by UTHealth Houston found measurable biological changes in firefighters' blood and urine 24 hours after fighting a fire, which may help identify early cancer risk. The study identified 75 significantly altered proteins in urine and 10 in blood serum, with several linked to cancer-related pathways.
Approximately 1 in 9 individuals in China will develop a digestive system cancer in their lifetime, with a staggering 1 in 12 succumbing to these diseases. The study reveals a profound 'risk transition' with colorectal cancer presenting the highest lifetime incidence risk.
Robotic gastrectomy reduces complications, blood loss, and hospital stay compared to laparoscopic surgery for gastric cancer patients, with benefits seen in both distal and total gastrectomy procedures. Longer procedures may be offset by improved visualization and enhanced dexterity.
Researchers have developed an oral therapy that protects healthy tissue from radiation while preserving radiation's ability to destroy cancer cells. The therapy, called XOlacta, is packaged in milk-derived extracellular vesicles and can be administered orally, reducing damage to tissues and preserving tumor treatment effectiveness.
Researchers developed a nanoplatform that addresses three barriers to TNBC immunotherapy by eliminating Tregs, destroying cancer cells, and activating innate immunity. In preclinical studies, the platform achieved 100% complete tumor regression and extended median survival beyond 70 days.
Researchers developed a first-in-class therapy targeting MYC, a protein involved in 70% of cancers, by disrupting its relationship with GSPT1. This approach showed strong anti-cancer activity in multiple types of blood cancers, including treatment-resistant models.
Researchers used super-resolution microscopy to track cancer drug sunitinib inside living cells, revealing its impact on cellular systems. The study found that sunitinib triggers a cascading breakdown of the systems that power, organize, and sustain the cell, contributing to cell function loss and survival.
Researchers found that Treg infiltration speed is the critical factor in determining PD-1 blockade immunotherapy outcomes. The team developed a mathematical model that accurately predicted this factor and validated it experimentally, identifying a promising new strategy to improve treatment outcomes.
A comparative study of 11,681 US cancer clinical trials reveals that industry-sponsored trials focus on single-agent drug therapies, while federally sponsored trials evaluate nontreatment interventions and rare cancer therapies. The study highlights the differences in trial design and objectives between industry and federal funding.
A large international study suggests that age may influence lung cancer biology and could help guide more personalized treatment strategies. Younger adults with non-small cell lung cancer are significantly more likely to have genetic alterations that can be matched with targeted therapies.
Researchers found that active participation in colorectal cancer screening was associated with a 43% lower risk of dying from the disease, compared to just a 26% lower risk for those invited to screening. This study highlights the importance of taking part in colorectal cancer screening to save lives.
The study aimed to determine the proportion of eligible patients consenting to either thyroid lobectomy or total thyroidectomy. It found that 93.5% of patients who would consent to randomization completed the assigned surgery. The results provide valuable insights for targeting enrollment in future multicenter trials.
Senescence unfolds in stages, not all at once, and can be suppressed without reversing the cells' permanent growth arrest. Different therapies create different forms of senescence, but ultimately lead to the same inflammatory response.
Researchers analyzed the make-up of oral microbes to detect signals associated with gastric and colorectal cancer, finding distinct signatures in patients with cancer. The study's findings could lead to the development of new, less-invasive screening tests for gastrointestinal cancers.
The PolyU research team has developed TRUECAM, an integrated AI framework that ensures data and model trustworthiness in cancer diagnosis. The framework can assess the level of an AI's confidence in its diagnostic outputs and proactively prompts pathologists to review cases when uncertainty is high.
Researchers create unified framework to explain MYC gene's role in cancer, identifying potential therapeutic targets. The MYC gene is a master regulator controlling cell growth, division, and metabolism, and is frequently altered in human cancer. A new study identifies PVT1 as a key regulatory hub for MYC activity, encoding two novel p...
A randomized clinical trial found that preoperative high-dose corticosteroids did not improve major postoperative outcomes in elective digestive cancer surgery. The study suggests that routine use of high-dose corticosteroids in this setting is not justified
Scientists discovered a previously missed DNA mutation pattern in colorectal cancer, found in 3 independent datasets of 2616 tumors, suggesting a new mechanism of DNA damage accumulation. The pattern appears relatively late in tumor development and is associated with small insertions and deletions in DNA.
A team of researchers at Columbia University has developed a multi-organ chip that mimics the process of cancer cells spreading to other organs, a critical phase of metastasis. The chip allows scientists to investigate cancer cell-tissue interactions in detail, revealing molecular pathways and therapeutic targets for metastasis.
Researchers at Pusan National University investigated how chronic environmental stress drives immune dysfunction in cold tumors, revealing a key driver of NK-cell maladaptation: the GDF15-AhR axis. This axis sustains activation of stress-sensing receptors, gradually exhausting NK cells and enabling immune escape.
Researchers discovered that exhausted T cells can lose the exhaustion marker LAG3 to escape tumors and confer long-lasting immunity to cancer in mice. These cells play a critical role in generating a strong, durable memory response, which is essential for effective cancer immunotherapy.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
βIII-tubulin is frequently overexpressed in various cancers and associated with aggressive tumor characteristics and poor therapeutic responses. Targeting βIII-tubulin-associated regulatory networks may provide new strategies to overcome treatment resistance.
Researchers identify IL-26 as a key regulator that reprograms tumor cells to evade immune attack, promoting immune escape and resistance to anti-PD-1 therapy. Targeting IL-26 may improve immunotherapy outcomes and lead to new treatments for cancer and chronic inflammatory diseases.
Researchers at UC Irvine propose a new framework to target mitochondrial dysfunction, a key contributor to immune effector cell-associated neurotoxicity syndrome, to make CAR T-cell therapy safer. The approach aims to repurpose existing drugs with established safety profiles, potentially accelerating the development of safer treatment ...
A decade-long review of Kids First DRC shows how shared data expands research opportunities across diseases, institutions, and scientific disciplines. The resource has supported findings with potential to improve diagnosis, risk assessment, and treatment in pediatric care.
A new study published in JAMA Internal Medicine found that pilots and flight attendants have statistically significantly higher rates of death from breast, central nervous system, and prostate cancers and melanoma. The study used a large dataset and accounted for various factors to determine the occupation's impact on mortality.
Purine metabolism aberrantly reprogrammed in cancer to drive hyperproliferation and metastasis; key enzymes act as active drivers of tumorigenesis. Selective targeting of purine metabolism networks presents promising next-generation anticancer strategy.